amrubicin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Amrubicin is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.   Wikipedia

Chemistry

  • SMILES: CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
  • InChIKey: VJZITPJGSQKZMX-XDPRQOKASA-N
  • Mol. Mass: 483.47
  • ALogP: 0.63
  • ChEMBL Molecules:
    amrubicin  
    amrubicin hydrochloride  
More Chemistry

Pharmacology

Alternative names

(+)-(7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride | (7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride | amrubicin | amrubicin hcl | amrubicin hydrochloride | sm 5887 | sm-5887

Organizations (21)

Research & Development (21)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Breast Neoplasms (Phase 2)

Lung Neoplasms (Phase 3)

Multiple Myeloma (Phase 1/Phase 2)

Neoplasms (Phase 1)

Sarcoma (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Thymoma (Phase 2)

Thymus Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 21

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue